Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination ophthalmic formulation containing hydroxypropyl guar, polyethylene glycol 400, and propylene glycol. It is primarily used as a lubricant eye drop for the management of dry eye disease. Polyethylene glycol 400 and propylene glycol act as demulcents (lubricants) that mimic natural tears to provide temporary relief from burning and discomfort due to dryness of the eye. Hydroxypropyl guar serves as a gelling agent that forms a soft, thin gel matrix in situ when exposed to the tear film, prolonging retention time on the ocular surface and enhancing mucous layer thickness[1][3][5]. This combination provides long-lasting relief from dry eye symptoms by stabilizing the tear film, improving ocular surface protection, and reducing evaporation[1][3][5]. The product is available over-the-counter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydroxypropyl-guar + polyethylene glycol 400 + propylene glycol.